

# Journal Pre-proof



Mid-term outcome of superior capsular reconstruction using doubled acellular human dermal allograft for irreparable rotator cuff tear

Martyn Snow, FRCS, Jan Herman Kuiper, MSc, PhD, Abilash Thimmegowda, FRCS, Vasanthakumar Ramsingh, FRCS, Mohammad Haikal, Priyadarshi Amit, MCh, FRCS

PII: S1058-2746(23)00505-0

DOI: <https://doi.org/10.1016/j.jse.2023.06.007>

Reference: YMSE 6460

To appear in: *Journal of Shoulder and Elbow Surgery*

Received Date: 8 November 2022

Revised Date: 29 May 2023

Accepted Date: 5 June 2023

Please cite this article as: Snow M, Kuiper JH, Thimmegowda A, Ramsingh V, Haikal M, Amit P, Mid-term outcome of superior capsular reconstruction using doubled acellular human dermal allograft for irreparable rotator cuff tear, *Journal of Shoulder and Elbow Surgery* (2023), doi: <https://doi.org/10.1016/j.jse.2023.06.007>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier Inc. on behalf of Journal of Shoulder and Elbow Surgery Board of Trustees.

Mid-term outcome of superior capsular reconstruction using doubled acellular human dermal allograft for irreparable rotator cuff tear

**Running title:** SCR using doubled human dermal allograft

Martyn Snow, FRCS<sup>1</sup>

Jan Herman Kuiper, MSc, PhD<sup>2,3</sup>

Abilash Thimmegowda, FRCS<sup>4</sup>

Vasanthakumar Ramsingh, FRCS<sup>5</sup>

Mohammad Haikal<sup>1,6</sup>

Priyadarshi Amit, MCh, FRCS<sup>1,7</sup>

<sup>1</sup> Department of Arthroscopy, Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, United Kingdom

<sup>2</sup> The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry, United Kingdom

<sup>3</sup> School of Pharmacy and Bioengineering, Keele University, Keele, United Kingdom

<sup>4</sup> Department of Trauma & Orthopaedics, Brighton and Sussex County Hospital, Brighton, United Kingdom

<sup>5</sup> Department of Trauma & Orthopaedics, United Lincolnshire Hospitals NHS Trust, Boston, United Kingdom

<sup>6</sup> Tanta University, Tanta, Egypt

<sup>7</sup> Department of Orthopaedics, Amrita Hospital, Faridabad, India

**Department and institution:**

Department of Arthroscopy, Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, United Kingdom

**Corresponding author:** Priyadarshi Amit, MCh, FRCS, Department of Orthopaedics, Amrita Hospital, Faridabad, India, 121002

Phone: (91)9910197128; Email: drpamit@gmail.com

South West - Central Bristol Research Ethics Committee provided ethical approval for this study (NHS HRA 16/SW/0251).

**Disclaimers:**

Funding: None of the authors or their family members have received any financial remuneration related to the subject of this article.

Conflicts of interest: The authors, their immediate families, and any research foundation with which they are affiliated did not receive any financial payments or other benefits from any commercial entity related to the subject of this article.

Journal Pre-proof

1 Mid-term outcome of superior capsular reconstruction using doubled acellular human dermal  
2 allograft for irreparable rotator cuff tear

3

#### 4 **Abstract**

5 **Purpose:** Thicker (folded) facia lata autografts have been shown to be superior to thinner grafts  
6 and single-layered acellular human dermal (HD) allografts for superior capsular reconstruction  
7 (SCR) in biomechanical studies. The aim of this study was to evaluate the mid-term clinical  
8 outcomes following SCR for irreparable supraspinatus tears using doubled (folded) HD  
9 allograft.

10 **Methods:** Thirty-two patients who had undergone SCR using doubled HD allograft between  
11 February 2012 through January 2020 were recruited in a continuous manner in this  
12 retrospective study. The inclusion criteria were SCR performed for irreparable supraspinatus  
13 tear and a minimum of two years follow-up. The primary outcome measure was the American  
14 Shoulder and Elbow Surgeons (ASES) score. The secondary outcome measures were  
15 complications and revision surgery. A subgroup analysis was performed between patients who  
16 received a “Standard” graft of mean 3mm thickness or a “Thick” graft of mean 4.4mm  
17 thickness.

18 **Results:** One patient was lost to follow-up. A total of 31 patients (31 shoulder joints) were  
19 analyzed with mean follow-up duration of 48 months (range, 25-96 months). Following  
20 surgery, there was significant improvement in ASES score from  $18.1 \pm 14.3$  (preoperative) to  
21  $76.3 \pm 25.1$  (postoperative) ( $P < 0.001$ ) with a satisfactory clinical outcome obtained in 83.8%  
22 of the patients. In a subset of eight patients completing five-years follow-up, clinical  
23 improvements were sustained. The percentage of patients with a clinically successful outcome  
24 was higher with thick grafts compared to patients with standard grafts, although this failed to  
25 reach statistical significance (94.4% vs 69.2%, RR=1.36, 95%CI 0.93-1.99,  $P = 0.13$ ). One  
26 patient within the standard group underwent revision surgery.

27 **Conclusion:** SCR for irreparable rotator cuff tears with doubled HD allograft results in  
28 improved clinical outcomes and low reoperation at mid-term follow-up duration.

29 **Level of evidence:** Level IV; Case Series; Treatment Study

30 **Keywords:** Dermal allograft; outcome; rotator cuff tear; superior capsular reconstruction.

31

32 Superior capsular reconstruction (SCR) provides an alternate option for irreparable  
33 supraspinatus tears with promising early outcomes reported, demonstrating excellent pain  
34 relief and restoration of function in younger individuals with preserved glenohumeral  
35 cartilage.<sup>3</sup> SCR was originally proposed by Mihata et al<sup>21</sup> using fascia lata (FL) autograft to re-  
36 establish superior stability and restore glenohumeral biomechanics.<sup>19</sup> Mihata et al<sup>17</sup> has  
37 published five-year clinical results of SCR using 5mm thick FL grafts demonstrating excellent  
38 outcomes with an improvement in ASES score of 63.3 points. Graft tear occurred in 10% of  
39 patients who consequently developed severe rotator cuff arthropathy. Through a biomechanical  
40 study, they have subsequently recommended further folding the graft in order to achieve a graft  
41 thickness of 6-8 mm in order to achieve better restoration of glenohumeral biomechanics.<sup>20</sup> A  
42 4 and 8mm thick (folded) FL graft reduced subacromial peak pressure after SCR, but only the  
43 thicker 8mm graft was able to decrease superior translation. However, this requires greater  
44 length of FL harvest and the potential for donor site morbidity. de Campos Azevedo et al<sup>6</sup>  
45 reported donor-site changes in 76.2% of their patients with 56.1% of patients being  
46 symptomatically bothered by their harvested thigh.

47 In 2015, Hirahara and Adams<sup>10</sup> first published the results of SCR using a single-layered  
48 acellular human dermal (HD) allograft of thickness between 2.5-3.5mm (Arthroflex; Lifenet  
49 Health, Virginia Beach, VA, USA). A recent systematic analysis of the available literature on  
50 the outcome following SCR has revealed that SCR using both FL and HD grafts results in  
51 significant improvement in short-term outcomes.<sup>5</sup> HD allograft offers a number of advantages  
52 over FL autograft including reduced donor-site morbidity, shorter operative time and easier  
53 preparation.<sup>1,5,10</sup> However, the disadvantages include higher cost along with concern over  
54 histological integration of the acellular graft and inferior biomechanics. In a cadaveric study,  
55 Mihata et al<sup>15</sup> has shown that compared to an 8mm FL graft, a single layer (2-5-3.5mm) dermal  
56 allograft only partially restored superior glenohumeral stability and was susceptible to 15%  
57 greater cyclical elongation, casting doubt over their long-term suitability. More recently  
58 biomechanical studies have investigated the potential benefits of folding/doubling dermal  
59 allografts, demonstrating superior results for thicker grafts.<sup>4,25</sup> Currently no clinical results on  
60 the use of folded/ doubled dermal allografts have been reported in the literature and the longest  
61 available mean follow-up using HD graft is up to two years.<sup>3,11,13,23</sup>

62 In 2012, when the senior author commenced SCR using dermal allograft, the thickest available  
63 graft was 1.27-1.78mm. Consequently, the dermal allograft was folded to create a graft

64 between 2.5-3.5mm in an attempt to obtain a thicker graft and replicate more closely the  
65 biomechanics of the original 5mm FL graft. Subsequently, a thicker HD graft (1.80-2.51mm)  
66 became available in 2016 and was used in similar folded fashion. The aim of this study was to  
67 evaluate the mid-term clinical outcome and complications following SCR using a doubled HD  
68 allograft and investigate the potential influence of graft thickness on clinical outcome.

69 We hypothesized that SCR using a doubled HD allograft results in successful clinical outcome  
70 at mid-term follow-up, with success defined as achieving the minimal clinically important  
71 difference in American Shoulder and Elbow Surgeons (ASES) Score (17 points).

## 72 **Materials and Methods**

73 A total of 43 patients who underwent SCR between 2012 and 2022 at a single center were  
74 retrospectively identified utilizing the hospital database and medical records. The inclusion  
75 criteria were SCR performed for irreparable posterosuperior rotator cuff tear involving  
76 supraspinatus with or without infraspinatus with a minimum of two years follow-up at the time  
77 of review and planned follow-up outcome measurement. The indication for SCR included  
78 failed non-operative treatment for a symptomatic irreparable supraspinatus tear (when the  
79 retracted tendon could not be advanced to the footprint after complete mobilization) or a  
80 supraspinatus tear with grade IV Goutallier fatty infiltration in patients who felt too young or  
81 active for reverse shoulder arthroplasty. Patients with evidence of acetabularization (Hamada  
82 3 or above) on x-ray or MRI were also not considered suitable. Intra-operative exclusion  
83 criteria were an irreparable tear of subscapularis or infraspinatus and/or evidence of significant  
84 arthropathy. Following screening, 32 patients satisfied the inclusion criterion of minimum of  
85 two years follow-up. One patient was lost to follow-up, hence was excluded from the study,  
86 leaving a final study population of 31 patients. Ethical approval for the study was obtained  
87 from the regional ethics committee. A power analysis was undertaken to estimate the required  
88 sample size for the main research hypothesis using dedicated software (G\*Power vs. 3.1.9.7,  
89 University of Dusseldorf, Germany). Assuming a mean improvement in ASES Score of 17  
90 points, a baseline and postop standard deviation (SD) of 20 and 16 points, respectively<sup>17</sup> and  
91 a correlation coefficient of 0.5 between baseline and follow-up score, the study would need  
92 12 patients to achieve 80% power at the two-tailed  $p=0.05$  significance level.

93 All surgeries were performed by a single surgeon (senior author) in the beach-chair position.  
94 After initial diagnostic arthroscopy to assess the suitability for the procedure, the subscapularis  
95 and infraspinatus were repaired when torn, using knotted suture anchors (4.5mm Healicoil;

96 Smith & Nephew, Andover, MA, USA). Additional procedures such as biceps tenotomy  
97 (N=16)/ tenodesis (N=2), acromioplasty (N=8), inferior capsular release (N=31) (for loss of  
98 passive range of motion) and suprascapular nerve decompression (N=6) (when Goutallier<sup>9</sup>  
99 grade 1 or 2 fatty atrophy of infraspinatus was present) were undertaken as deemed necessary  
100 (Table 1). After preparation of the glenoid and humeral footprint, two glenoid anchors (2.8 Q-  
101 Fix; Smith & Nephew, Austin, TX, USA) and two medial row anchors (4.5mm Healicoil;  
102 Smith & Nephew, Andover, MA, USA) were inserted.

103 The graft used was an acellular human dermal allograft (Graftjacket; Wright Medical  
104 Technology, Memphis, TN, USA) which was doubled (folded) in all patients and sewn across  
105 three edges using a 2.0 vicryl running suture (Fig 1.). From 2012 to mid 2016 a graft of mean  
106 1.5mm thickness (tolerances 1.27-1.78mm, Graftjacket, maxforce) was used which, when  
107 folded had a overall mean thickness of 3mm. These patients will hereby be referred to as the  
108 ‘Standard’ graft group. From mid 2016 onwards, a graft with mean thickness of 2.2mm  
109 (tolerances 1.80-2.51mm, Graftjacket, maxforce extreme) was used which, when folded had a  
110 overall mean thickness of 4.4mm . These patients will be hereby referred as the ‘Thick’ graft  
111 group. All grafts were pre-tensioned to remove any initial creep, which resulted in a consistent  
112 minor reduction in thickness which was not quantified.

113 The graft was fixed medially on the glenoid using the double loaded anchors via two simple  
114 sutures and a double pulley technique. The lateral fixation was achieved with a double pulley  
115 and a knotless suture bridge (with 1 tape from each anchor) using two knotless lateral row  
116 anchors (Multi-Fix S; Smith & Nephew, Austin, TX, USA) with the shoulder in 20-30 degree  
117 of abduction and 20 degree of forward flexion (Fig 2). A posterior margin convergence  
118 between the graft and infraspinatus was undertaken in all patients and an anterior margin  
119 convergence was undertaken with the interval tissue when possible.

120 Postoperative rehabilitation included six weeks of immobilization in an abduction sling, with  
121 passive external rotation allowed. Active assisted range of motion was commenced at 6 week  
122 and strengthening exercises at 3 months. A return to full activity, including sporting activity  
123 was resumed at 9-12 months.

124 The American Shoulder and Elbow Surgeons (ASES) score was the primary outcome measure,  
125 and was recorded preoperatively and repeated following recruitment into the study. A ‘clinical  
126 success’ or satisfactory outcome was defined as a 17 point improvement in the ASES, which  
127 corresponds to the validated minimal clinically important difference (MCID) in rotator cuff

128 repair.<sup>3,7,26</sup> An improvement in ASES score of less than 17 points was considered an  
129 unsatisfactory outcome or 'clinical failure'. Secondary outcome measure were complications  
130 and or revision surgeries.

131 All surgeries were performed in a public health system and so routine postoperative evaluation  
132 using Magnetic Resonance Imaging (MRI) was not performed unless there was concern  
133 regarding the patient's recovery or following injury. All scans were assessed for graft healing  
134 by a fellowship trained musculoskeletal radiologist. Failure of the graft-bone interface at the  
135 glenoid or humerus or mid-substance discontinuity of the graft was considered a radiological  
136 graft failure.

### 137 *Statistical analysis*

138 The statistical analysis was performed using SPSS 22.0 (IBM Corp, Armonk, NY, USA). The  
139 descriptive data was presented as absolute number or percentages for categorical variables  
140 such as demographics and operative parameters and mean  $\pm$  SD for continuous variables such  
141 as ASES scores. The pre and postoperative outcomes were compared with a paired t-test to  
142 assess the improvement in ASES score. Further comparison was performed in the two groups  
143 of patients based on the thickness of graft. The outcome between the patients with thin and  
144 thick graft was compared with an unpaired t-test for continuous variables and Fisher exact test  
145 for categorical variables. The P value of less than 0.05 was considered as statistically  
146 significant.

### 147 **Results**

148 A total of 31 patients (31 shoulders) formed the final study group for analysis. The patient's  
149 demographic and intra-operative variables are presented in table 1. The mean follow-up was  
150 48 months (range, 25-96 months) (Fig 3).

151 Table 2 describes the clinical outcome and complications in the study population. There was  
152 significant improvement in mean ASES score for the whole cohort of patients. Twenty six  
153 (83.8%) patients were defined as having a satisfactory outcome ( $>17$  point improvement in  
154 ASES score), with a mean ASES score of  $85.6 \pm 12.3$  points. Five (16.1%) patients failed to  
155 achieve the MCID in ASES and were defined as having an unsatisfactory outcome. The two  
156 groups were wide apart, with the 26 defined as satisfactory doing very well (mean  
157 improvement 69 points) and the five whose outcome was unsatisfactory having essential no  
158 change in outcome (mean change 3 points; Table 2). Two of these five patients experienced a



159 deterioration in the ASES score, one of which (3.2%) underwent revision to reverse shoulder  
160 arthroplasty.

161 Eight patients had completed a minimum of five-years follow-up (mean, 71.3 months; range,  
162 61-96 months), with an overall significant improvement in ASES score. A satisfactory  
163 outcome was maintained in five (62.5%) patients with a mean ASES score of  $90 \pm 5.8$  points.  
164 Three (37.5%) patients failed to achieve the MCID and were classified as clinical failures,  
165 however none required revision surgery.

166 Thirteen patients underwent SCR using a standard graft, while a thick graft was used in 18  
167 patients (Table 3). Both groups had significant improvement in the ASES score following  
168 surgery. The patients with thick grafts had a higher improvement but the difference was not  
169 statistically significant ( $p=0.18$ ). There was greater proportion of patients achieving the MCID  
170 in the thick graft group compared to the standard graft, however the difference failed to reach  
171 statistical significance (94.4% versus 69.2%,  $RR=1.36$  (95% CI 0.93 to 1.99,  $P = 0.13$ ). There  
172 were four clinical failures with the standard graft, one which occurred at 12 months, one at 30  
173 months and two after 5 years post-surgery. The three patients with confirmed radiological graft  
174 failure noted on MRI, had SCR using the standard graft. The single revision surgery was  
175 performed in a patient with a standard graft who failed at 12 months.

176 An MRI scan was performed in eight patients where graft failure was noted in three patients  
177 at a mean follow-up at 30 months, two on the humeral side and one on the glenoid side.  
178 Clinically two had an unsatisfactory outcome, whereas, one patient had a clinically satisfactory  
179 outcome despite radiological graft failure. The patient who underwent revision to reverse  
180 shoulder arthroplasty at 1.5 years post-SCR had a clinical and graft failure noted on MRI at  
181 12 months. There were no further complications in the study cohort. On MRI, the two folds of  
182 the graft were found integrated into one layer in six patients. In two patients the graft remained  
183 as 2 separate folds, however both grafts were intact and were deemed a clinical success based  
184 on ASES (Fig 4). The graft thickness remained comparable to the intra-operative thickness  
185 with no appreciable thinning.

## 186 **Discussion**

187 The main finding of this study was that SCR using a doubled HD allograft leads to significant  
188 improvements in pain and function at mid-term follow-up with a low reoperation rate. At a  
189 mean follow-up of 48 months, 83.8% of patients were defined as having a clinically successful

190 outcome. There was no evidence for improved ASES scores in patients receiving thick grafts  
191 or a greater proportion achieving the MCID when compared to standard grafts.

192 The superior capsule, reinforced by the rotator cuff tendons, serves as a static stabilizer of the  
193 shoulder preventing superior translation of humeral head, the loss of this restraint results in  
194 superior glenohumeral translation, secondary subacromial impingement and potential  
195 pseudoparalysis.<sup>8,10,12,14</sup>

196 Clinically, SCR in rotator cuff deficient shoulders has been shown to result in significant  
197 improvements in patient reported outcome measures, range of movement, strength, return to  
198 sports and reversal of pseudoparalysis regardless of the type of graft used.<sup>1,2,13,14,16,18,23</sup> The  
199 reported two-year results of SCR using single-layered HD allografts (1-3.5mm thick) have  
200 been encouraging.<sup>7,11,23,24</sup> In a case series of 38 patients, Pennington et al<sup>23</sup> showed a success  
201 rate of 94.8% with a significant improvement in ASES score of 35.8 points (from 49.5 to 85.3)  
202 at two years post-surgery. Burkhart et al<sup>3</sup> published a single-surgeon series of 41 patients with  
203 mean follow-up of 34 months where ASES score improved 37 points (from  $52 \pm 3$  to  $89 \pm 2$ )  
204 at final follow-up, with satisfactory outcome in 81% of patients. Similarly, Lacheta et al<sup>13</sup>, at  
205 mean follow-up of 2.1 years, demonstrated satisfactory outcome in 85% of their patients with  
206 a significant improvement in ASES of 29.9 points (from 54.0 to 83.9) at final follow-up.  
207 However, the mid-term results of SCR using HD allograft have not previously been reported.  
208 The current study revealed a significant improvement in ASES score of 58.2 points (from  $18.1$   
209  $\pm 14.3$  to  $76.3 \pm 25.1$ ) with 83.8% achieving clinical success at a mean follow-up of 4 years in  
210 the entire cohort. Within the group with follow-up beyond 5 years (mean 5.9 years) the  
211 proportion considered a clinical success was smaller (5/8 or 63%). However, just like in the  
212 full cohort, these five patients had a very large mean improvement (76 ASES points),  
213 demonstrating sustained clinical improvement. All patients with follow-up beyond 5 years  
214 received the standard graft and so it is unknown if the results when using a thicker graft are  
215 more durable. The finding of one clinical failure in the thick group at mean follow-up of 34.7  
216 is encouraging.

217 The preoperative scores in this study are considerably lower than those previously reported,  
218 consequently the final overall score is lower in comparison, particularly when the patients with  
219 unsatisfactory outcome are included in the analysis. It is difficult to ascertain why the preop  
220 scores are so much lower and may relate to the time to surgery within a public health system.  
221 However, the improvement in ASES score in the patients with a satisfactory outcome are

222 comparable to the previous results and are maintained beyond 5 years. These results  
223 demonstrate that SCR using doubled HD allograft can be durable in the mid-term.

224 The thickness of the graft is the main determinant of its biomechanical function when used for  
225 superior capsule reconstruction. Nimura et al<sup>22</sup> determined that the native superior capsule  
226 varied in thickness at its insertion on the humerus between 4-9mm, being thicker posteriorly.  
227 The final thickness of the FL autografts currently recommended is 6-8mm, which is obtained  
228 by folding the graft multiple times.<sup>19</sup> The maximal thickness of HD allografts is generally up  
229 to 3.5mm<sup>7,23</sup> and consequently all prior clinical results have been reported using grafts which  
230 at best correspond to the “standard” grafts in this study. Cline et al<sup>4</sup> in a biomechanical study  
231 compared 7.3mm thick FL allograft, with 6.4mm doubled and 2.5mm single layered HD  
232 allograft. At 0° abduction, all SCR conditions significantly decreased superior translation  
233 compared with the massive tear but did not restore translation ( $P < .05$ ) to intact. Fascia lata  
234 and double-layer dermis SCR restored superior translation to intact at 30° and 60° of abduction,  
235 but single-layer dermis did not. In addition, single-layer dermis graft thickness significantly  
236 decreased more than fascia lata during testing ( $P = 0.02$ ). Whilst the doubled HD allograft used  
237 was thinner than the thick grafts used in this study (6.4mm vs 4.4mm) it confirms the potential  
238 advantages of folding in order to increase graft thickness. The trend towards improved results  
239 in the thick group (94.4% versus 69% satisfactory results) may reflect this greater potential to  
240 resist superior translatory forces more effectively and consequently reduce the cyclical  
241 elongation seen with thinner grafts. A thicker graft may also have a greater interposition effect.  
242 One final potential advantage of a doubled HD allograft compared to a single layer, is that the  
243 graft can be implanted with the two porous surfaces on the superior and inferior aspect. This  
244 may provide greater surface area and porosity with consequent increased biological integration  
245 and vascular ingrowth from the adjacent bone and the subacromial bursa.

246 This study has a number of limitations. Firstly, this was a retrospective case series with a  
247 relatively small sample size. The small number of patients in our study cohort is probably one  
248 reason for lack of significance in statistical comparison between the standard and thick graft  
249 groups despite the trend towards improvements in the thick group. Likewise, small sample size  
250 could also explain the high percentage of clinical failures in patients over five years follow-up  
251 in preliminary results, because they may represent our learning curve with this technique. A  
252 future randomized trial of thick versus thin allograft would need 70 patients (35 per group)  
253 based on a difference in ASES Score of 17 points, the overall SD of 25 points in this study,  
254 and assuming 80% power at the two-tailed  $p=0.05$  level. Nevertheless, considering the first

255 description of the superior capsule was in 2012, the 2-8 year results presented in this study is  
256 the first to provide potential valuable information as to the mid-term outcome of SCR with HD  
257 allograft. Secondly, MRI scans and x-rays were not performed in all patients post-surgery,  
258 therefore, the true graft failure rate and subsequent Hamada grade in this study is unknown.  
259 The study was undertaken in a public health system where postoperative imaging is not routine.  
260 Ultimately, however, the most important outcome with any treatment, is the level and length  
261 of any clinical improvement. Thirdly, the functional outcome was measured in all patients at a  
262 single time point, on recruitment to the study. Hence, it was difficult to assess the change in  
263 ASES score over time in the patients with longer follow-up. Moreover, the length of follow-  
264 up differed between the two groups which could introduce a bias. Fourth, this study is a single-  
265 surgeon series, which may affect the generalizability of our result. Fifth, there was a minor  
266 reduction in graft thickness with the pre-tension applied to remove creep. However, the  
267 reduction in thickness was experienced by all grafts in the study to a similar degree and so is  
268 unlikely to have affected the clinical outcome between groups. Sixth, almost half of our study  
269 cohort required infraspinatus and or subscapularis repair in addition to SCR which might have  
270 contributed to the improved ASES scores. The positive impact of balancing anterior and  
271 posterior force couples is well established and is a pre-requisite for SCR, but this does not  
272 account for the similar gains in ASES in those patients where repair was not required. Lastly,  
273 the standard grafts were used for the first half of the study and so the mean follow-up is longer  
274 in this group. This has likely contributed to an anticipated increase in clinical failures (37.5%)  
275 which was observed in these patients . Whilst comparative follow-up is needed to confirm this  
276 observation, thicker HD grafts have the potential to provide a more durable outcome.

## 277 **Conclusions**

278 Superior capsular reconstruction for irreparable supraspinatus tears with doubled human  
279 dermal allograft results in an 83.8% clinical success rate at mean follow-up of 48 months.  
280 There was no evidence to suggest that thicker dermal allograft may provide improved results  
281 and a larger sample size would be needed for such a study.

## 282 **References**

- 283 1. Altintas B, Scheidt M, Kremser V, Boykin R, Bhatia S, Sajadi KR, et al. Superior capsule  
284 reconstruction for irreparable massive rotator cuff tears: Does it make sense? A systematic  
285 review of early clinical evidence. *Am J Sports Med.* 2020;48(13):3365-75. doi:  
286 10.1177/0363546520904378.

- 287 2. Burkhart SS, Hartzler RU. Superior capsular reconstruction reverses profound  
288 pseudoparalysis in patients with irreparable rotator cuff tears and minimal or no  
289 glenohumeral arthritis. *Arthroscopy*. 2019;35(1):22-8. doi: 10.1016/j.arthro.2018.07.023.
- 290 3. Burkhart SS, Prankun JJ, Hartzler RU. Superior capsular reconstruction for the  
291 operatively irreparable rotator cuff tear: Clinical outcomes are maintained 2 years after  
292 surgery. *Arthroscopy*. 2020;36(2):373-80. doi: 10.1016/j.arthro.2019.08.035.
- 293 4. Cline KE, Tibone JE, Ihn H, Akeda M, Kim BS, McGarry MH, et al. Superior capsule  
294 reconstruction using fascia lata allograft compared with double- and single-layer dermal  
295 allograft: A biomechanical study. *Arthroscopy*. 2021;37(4):1117-25. doi:  
296 10.1016/j.arthro.2020.11.054.
- 297 5. de Campos Azevedo CI, Andrade R, Ângelo ACLPG, Espregueira-Mendes J, Ferreira N,  
298 Sevivas N. Fascia lata autograft versus human dermal allograft in arthroscopic superior  
299 capsular reconstruction for irreparable rotator cuff tears: A systematic review of clinical  
300 outcomes. *Arthroscopy*. 2020;36(2):579-91. doi: 10.1016/j.arthro.2019.08.033.
- 301 6. de Campos Azevedo CI, Ângelo ACLPG, Vinga S. Arthroscopic superior capsular  
302 reconstruction with a minimally invasive harvested fascia lata autograft produces good  
303 clinical results. *Orthop J Sports Med*. 2018;6(11):2325967118808242. doi:  
304 10.1177/2325967118808242.
- 305 7. Denard PJ, Brady PC, Adams CR, Tokish JM, Burkhart SS. Preliminary results of  
306 arthroscopic superior capsule reconstruction with dermal allograft. *Arthroscopy*.  
307 2018;34(1):93-9. doi: 10.1016/j.arthro.2017.08.265.
- 308 8. Deutsch A, Altchek DW, Schwartz E, Otis JC, Warren RF. Radiologic measurement of  
309 superior displacement of the humeral head in the impingement syndrome. *J Shoulder  
310 Elbow Surg*. 1996;5:186-93.
- 311 9. Goutallier D, Postel J-M, Gleyze P, Leguilloux P, Van Driessche S. Influence of cuff  
312 muscle fatty infiltration on anatomic and functional outcomes after simple suture of full-  
313 thickness tears. *J Shoulder Elbow Surg*. 2003;12:550-554. doi: 10.1016/s1058-  
314 2746(03)00211-8.
- 315 10. Hirahara AM, Adams CR. Arthroscopic superior capsular reconstruction for treatment of  
316 massive irreparable rotator cuff tears. *Arthrosc Tech*. 2015;4:637-41. doi:  
317 10.1016/j.eats.2015.07.006.

- 318 11.Hirahara AM, Andersen WJ, Panero AJ. Superior capsular reconstruction: Clinical  
319 outcomes after minimum 2-year follow-up. *Am J Orthop* (Belle Mead NJ).  
320 2017;46(6):266-78. No doi
- 321 12.Ishihara Y, Mihata T, Tamboli M, Nguyen L, Park KJ, McGarry MH, et al. Role of the  
322 superior shoulder capsule in passive stability of the glenohumeral joint. *J Shoulder Elbow*  
323 *Surg.* 2014;23(5):642-48. doi: 10.1016/j.jse.2013.09.025.
- 324 13.Lacheta L, Horan MP, Schairer WW, et al. Clinical and imaging outcomes after  
325 arthroscopic superior capsule reconstruction with human dermal allograft for irreparable  
326 posterosuperior rotator cuff tears: A minimum 2-year follow-up. *Arthroscopy.*  
327 2020;36(4):1011-9. doi: 10.1016/j.arthro.2019.12.024.
- 328 14.Makovicka JL, Chung AS, Patel KA, Deckey DG, Hassebrock JD, Tokish JM. Superior  
329 capsule reconstruction for irreparable rotator cuff tears: A systematic review of  
330 biomechanical and clinical outcomes by graft type. *J Shoulder Elbow Surg.*  
331 2020;29(2):392-401. doi: 10.1016/j.jse.2019.07.005.
- 332 15.Mihata T, Bui CNH, Akeda M, Cavagnaro MA, Kuenzler M, Peterson AB, et al. A  
333 biomechanical cadaveric study comparing superior capsule reconstruction using fascia lata  
334 allograft with human dermal allograft for irreparable rotator cuff tear. *J Shoulder Elbow*  
335 *Surg.* 2017;26(12):2158-66. doi: 10.1016/j.jse.2017.07.019.
- 336 16.Mihata T, Lee TQ, Fukunishi K, Itami Y, Fujisawa Y, Kawakami T et al. Return to sports  
337 and physical work after arthroscopic superior capsule reconstruction among patients with  
338 irreparable rotator cuff tears. *Am J Sports Med.* 2018;46(5):1077-83. doi:  
339 10.1177/0363546517753387.
- 340 17.Mihata T, Lee TQ, Hasegawa A, Fukunishi K, Kawakami T, Fujisawa Y, et al. Five-year  
341 follow-up of arthroscopic superior capsule reconstruction for irreparable rotator cuff tears.  
342 *J Bone Joint Surg Am.* 2019;101(21):1921-30. doi: 10.2106/JBJS.19.00135.
- 343 18.Mihata T, Lee TQ, Hasegawa A, Kawakami T, Fukunishi K, Fujisawa Y, et al.  
344 Arthroscopic superior capsule reconstruction can eliminate pseudoparalysis in patients  
345 with irreparable rotator cuff tears. *Am J Sports Med.* 2018;46(11):2707-16. doi:  
346 10.1177/0363546518786489.



- 347 19. Mihata T, Lee TQ, Watanabe C, Fukunishi K, Ohue M, Tsujimura T, et al. Clinical results  
348 of arthroscopic superior capsule reconstruction for irreparable rotator cuff tears.  
349 *Arthroscopy*. 2013;29(3):459-70. doi: 10.1016/j.arthro.2012.10.022.
- 350 20. Mihata T, McGarry MH, Kahn T, Goldberg I, Neo M, Lee TQ. Biomechanical effect of  
351 thickness and tension of fascia lata graft on glenohumeral stability for superior capsule  
352 reconstruction in irreparable supraspinatus tears. *Arthroscopy*. 2016;32(3):418-26. doi:  
353 10.1016/j.arthro.2015.08.024.
- 354 21. Mihata T, McGarry MH, Pirolo JM, Kinoshita M, Lee TQ. Superior capsule reconstruction  
355 to restore superior stability in irreparable rotator cuff tears: a biomechanical cadaveric  
356 study. *Am J Sports Med*. 2012;40(10):2248-55. doi: 10.1177/0363546512456195.
- 357 22. Nimura A, Kato A, Yamaguchi K, Mochizuki T, Okawa A, Sugaya H, et al. The superior  
358 capsule of the shoulder joint complements the insertion of the rotator cuff. *J Shoulder  
359 Elbow Surg*. 2012;21(7):867-72. doi: 10.1016/j.jse.2011.04.034.
- 360 23. Pennington WT, Bartz BA, Pauli JM, Walker CE, Schmidt W. Arthroscopic superior  
361 capsular reconstruction with acellular dermal allograft for the treatment of massive  
362 irreparable rotator cuff tears: Short-term clinical outcomes and the radiographic parameter  
363 of superior capsular distance. *Arthroscopy*. 2018;34(6):1764-73. doi:  
364 10.1016/j.arthro.2018.01.009.
- 365 24. Ravenscroft MJ, Riley JA, Morgan BW, Sandher DS, Odak SS, Joseph P. Histological  
366 incorporation of acellular dermal matrix in the failed superior capsule reconstruction of  
367 the shoulder. *J Exp Orthop*. 2019;6(1):21. doi: 10.1186/s40634-019-0189-1.
- 368 25. Scheiderer B, Kia Cameron, Obopilwe E, Johnson JD, Cote MP, Imhoff FB, et al.  
369 Biomechanical effect of superior capsule reconstruction using a 3-mm and 6-mm thick  
370 acellular dermal allograft in a dynamic shoulder model. *Arthroscopy*. 2020;36(2):355-64.  
371 doi: 10.1016/j.arthro.2019.08.026.
- 372 26. Tashjian RZ, Deloach J, Green A, Porucznik CA, Powell AP. Minimal clinically important  
373 differences in ASES and simple shoulder test scores after nonoperative treatment of rotator  
374 cuff disease. *J Bone Joint Surg Am*. 2010;92(2):296-303. doi: 10.2106/JBJS.H.01296.

375 **Legends**

376 **Figure 1:** Doubled HD allograft prepared by folding the graft and running sutures across the  
377 edges

378 **Figure 2:** Arthroscopic image showing the doubled HD allograft over the glenohumeral joint  
379 to reconstruct the superior capsule

380 **Figure 3:** Chart showing the number of patients in relation to follow-up duration

381 **Figure 4:** MR images at 1-year post-surgery showing (a) biologic integration of two layers of  
382 allograft into one layer and (b) the graft remaining as two distinct layers

383 **Table 1:** Demographics of the 31 patients comprising the study population

384 **Table 2:** ASES scores and complications following surgery

385 **Table 3:** Clinical outcome score and complications with regards to graft thickness.



<b>Parameters</b>	<b>Result, n (%)</b>
Mean age, yrs (range)	64 (47-81)
Male, %	14 (45.1%)
Right:Left*	22:9
Prior shoulder surgeries, %	5 (16.1%)
Acromioplasty, %	8 (25.8%)
Inferior capsular release, %	31 (100%)
Infraspinatus repair, %	15 (48.3%)
Subscapularis repair, %	13 (41.9%)
Biceps tenotomy, %	16 (51.6%)
Biceps tenodesis, %	2 (6.4%)
Anterior side-to-side suturing, %	8 (25.8%)
Posterior side-to-side suturing, %	31 (100%)
Suprascapular nerve release, %	6 (19.3%)

\* side of surgery

Outcomes	2-5 years f/u*	> 5 years f/u <sup>#</sup>
Mean f/u (months)	48 (range 25-96)	71.3 (range 61-96)
Overall outcome	n = 31	n = 8
<i>Pre-operative</i>	18.1 ± 14.3	21.2 ± 17.4
<i>Post-operative</i>	76.3 ± 25.1	69.9 ± 29.2
<i>Change</i>	58.2 ± 30.4	48.8 ± 38.4
<i>P value</i>	< 0.001	0.008
Satisfactory outcome	n = 26	n = 5
<i>Pre-operative</i>	16.7 ± 12.8	14.3 ± 10.8
<i>Post-operative</i>	85.6 ± 12.3	90 ± 5.8
<i>Change</i>	68.9 ± 18.4	75.7 ± 8.9
<i>P value</i>	< 0.001	< 0.001
Unsatisfactory outcome	n = 5	n = 3
<i>Pre-operative</i>	25.3 ± 20.5	32.7 ± 22.7
<i>Post-operative</i>	27.9 ± 16.6	36.7 ± 15.9
<i>Change</i>	2.6 ± 13.5	3.9 ± 12.7
<i>P value</i>	0.687	0.409
Radiological graft failure	3	2
Reoperation	1	0


\* 2-5 years f/u indicates the entire study population,

<sup>#</sup> > 5 years f/u indicates subset of patients who had completed 5 years follow up duration.


Outcomes	Standard graft	Thick graft	P value
Mean f/u (months)	63.8 (range 51-96)	34.7 (range 25-46)	< 0.001
Overall outcome	n = 13	n = 18	
<i>ASES Pre-op</i>	21.2 ± 19.3	15.8 ± 9.1	0.313
<i>ASES Post-op</i>	70.7 ± 24.6	80.3 ± 21.8	0.299
<i>ASES change</i>	49.5 ± 33.1	64.5 ± 27.5	0.180
<i>P value</i>	< 0.001	< 0.001	
Satisfactory outcome	n = 9	n = 17	0.13
<i>ASES Pre-op</i>	19.3 ± 18.4	15.2 ± 9.1	0.463
<i>ASES Post-op</i>	87.9 ± 8.6	84.3 ± 14.1	0.497
<i>ASES change</i>	68.6 ± 16.2	69.1 ± 20.1	0.955
<i>P value</i>	< 0.001	< 0.001	
Unsatisfactory outcome	n = 4	n = 1	
<i>ASES Pre-op</i>	25.4 ± 23.6	25	0.494
<i>ASES Post-op</i>	31.9 ± 14.2	11.7	0.169
<i>ASES change</i>	8.3 ± 13.7	-13.3	0.112
<i>P value</i>	0.342	-	
Radiological graft failure	3	0	
Reoperation	1	0	0.274




Journal Pre-proof




Journal Pre-proof





Journal Pre-proof



Journal Pre-proof